Pelletier: Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Pelletier et al., Ear, Nose & Throat Journal, doi:10.1177/0145561320957237 (In Vitro)

Pelletier et al., Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory.., Ear, Nose & Throat Journal, doi:10.1177/0145561320957237 (In Vitro)

Sep 2020 Source PDF

Twitter
Facebook

All Studies Meta

In Vitro study testing nasal and oral PVP-I formulations with 60 second exposure time, showing complete inactivation of SARS-CoV-2 with all concentrations (1% to 5% PVP-I).

8 In Vitro studies support the efficacy of povidone-iodine [Anderson, Bidra, Frank, Hassandarvish, Meister, Pelletier, Tucker, Xu].

Important missing comments or errors? Let us know.

1. Anderson et al., Infectious Diseases and Therapy, doi:10.1007/s40121-020-00316-3, Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease, https://link.springer.com/article/10.1007%2Fs40121-020-00316-3.

2. Bidra et al., Journal of Prosthodontics, doi:10.1111/jopr.13209, Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse, https://onlinelibrary.wiley.com/doi/full/10.1111/jopr.13209.

3. Frank et al., JAMA Otolaryngol Head Neck Surg, doi:10.1001/jamaoto.2020.3053, In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2, https://jamanetwork.com/journals/j..otolaryngology/fullarticle/2770785.

4. Hassandarvish et al., British Dental Journal volume, doi:10.1038/s41415-020-1794-1, Povidone iodine gargle and mouthwash, https://www.nature.com/articles/s41415-020-1794-1.

5. Meister et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiaa471, Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2, https://academic.oup.com/jid/article/222/8/1289/5878067.

6. Pelletier et al., Ear, Nose & Throat Journal, doi:10.1177/0145561320957237, Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2), https://journals.sagepub.com/doi/10.1177/0145561320957237.

7. Tucker et al., bioRxiv, doi:10.1101/2021.01.31.426979 , In vitro inactivation of SARS-CoV-2 with 0.5% povidone iodine nasal spray (Nasodine) at clinically relevant concentrations and timeframes using tissue culture and PCR based assays, https://www.biorxiv.org/content/10.1101/2021.01.31.426979v1.

8. Xu et al., Pathogens, doi:10.3390/pathogens10030272, Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro, https://www.mdpi.com/2076-0817/10/3/272.

Pelletier et al., 21 Sep 2020, peer-reviewed, 6 authors.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Povidone-Iod..All

Abstract: Basic Science Study: Trends in Practice & Training Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) Ear, Nose & Throat Journal 2021, Vol. 100(2S) 192S–196S ª The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0145561320957237 journals.sagepub.com/home/ear Jesse S. Pelletier, MD1, Belachew Tessema, MD, FACS2,3 , Samantha Frank, MD3 , Jonna B. Westover4, Seth M. Brown, MD2,3, and Joseph A. Capriotti, MD5 Abstract Introduction: Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the global pandemic of coronavirus disease 2019 (COVID-19). From the first reported cases in December 2019, the virus has spread to over 4 million people worldwide. Human-to-human transmission occurs mainly through the aerosolization of respiratory droplets. Transmission also occurs through contact with contaminated surfaces and other fomites. Improved antisepsis of human and nonhuman surfaces has been identified as a key feature of transmission reduction. There are no previous studies of povidone iodine (PVP-I) against SARS-CoV-2. This study evaluated nasal and oral antiseptic formulations of PVP-I for virucidal activity against SARS-CoV-2. This is the first report on the efficacy of PVP-I against the virus that causes COVID-19. Methods: Povidone iodine nasal antiseptic formulations and PVP-I oral rinse antiseptic formulations from 1% to 5% concentrations as well as controls were studied for virucidal efficacy against the SARS-CoV-2. Test compounds were evaluated for ability to inactivate SARS-CoV-2 as measured in a virucidal assay. SARS-CoV-2 was exposed directly to the test compound for 60 seconds, compounds were then neutralized, and surviving virus was quantified. Results: All concentrations of nasal antiseptics and oral rinse antiseptics evaluated completely inactivated the SARS-CoV-2. Conclusions: Nasal and oral PVP-I antiseptic solutions are effective at inactivating the SARS-CoV-2 at a variety of concentrations after 60-second exposure times. The formulations tested may help to reduce the transmission of SARS-CoV-2 if used for nasal decontamination, oral decontamination, or surface decontamination in known or suspected cases of COVID-19. Keywords povidone iodine, SARS-CoV-2, nasal rinse, oral rinse

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit